Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

EMPRISE EU, East Asia Study Grp, Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Leo Niskanen, Krishnarajah Nirantharakumar

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Originalspråkengelska
Artikelnummer233
TidskriftCardiovascular Diabetology
Volym22
Nummer1
Antal sidor12
ISSN1475-2840
DOI
StatusPublicerad - 31 aug. 2023
MoE-publikationstypA1 Tidskriftsartikel-refererad

Bibliografisk information

Publisher Copyright:
© 2023, BioMed Central Ltd., part of Springer Nature.

Vetenskapsgrenar

  • 3121 Allmänmedicin, inre medicin och annan klinisk medicin

Citera det här